ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 39 filers reported holding ESSA PHARMA INC in Q2 2023. The put-call ratio across all filers is 1.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,080 | +162.8% | 12,000 | +129.7% | 0.00% | – |
| Q2 2023 | $14,107 | -9.1% | 5,225 | 0.0% | 0.00% | – |
| Q1 2023 | $15,518 | +19.4% | 5,225 | 0.0% | 0.00% | – |
| Q4 2022 | $13,000 | +62.5% | 5,225 | +23.7% | 0.00% | – |
| Q3 2022 | $8,000 | -38.5% | 4,225 | 0.0% | 0.00% | – |
| Q2 2022 | $13,000 | -50.0% | 4,225 | 0.0% | 0.00% | – |
| Q1 2022 | $26,000 | -60.0% | 4,225 | -7.3% | 0.00% | – |
| Q4 2021 | $65,000 | +27.5% | 4,559 | -28.8% | 0.00% | – |
| Q3 2021 | $51,000 | -92.3% | 6,401 | -72.4% | 0.00% | -100.0% |
| Q2 2021 | $662,000 | +3.8% | 23,165 | +5.6% | 0.00% | -50.0% |
| Q1 2021 | $638,000 | +282.0% | 21,945 | +56.8% | 0.00% | – |
| Q4 2020 | $167,000 | +153.0% | 14,000 | +47.4% | 0.00% | – |
| Q3 2020 | $66,000 | +11.9% | 9,500 | 0.0% | 0.00% | – |
| Q2 2020 | $59,000 | +73.5% | 9,500 | +11.8% | 0.00% | – |
| Q1 2020 | $34,000 | – | 8,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,145,117 | $12,310,997 | 1.28% |
| BVF INC/IL | 8,748,629 | $25,983,428 | 0.95% |
| Ally Bridge Group (NY) LLC | 236,583 | $702,652 | 0.92% |
| PFM Health Sciences, LP | 4,161,461 | $12,359,539 | 0.55% |
| Bellevue Group AG | 7,898,583 | $23,458,792 | 0.34% |
| Rhenman & Partners Asset Management AB | 356,500 | $1,051,675 | 0.12% |
| Orbimed Advisors | 1,198,337 | $3,559,061 | 0.07% |
| Privium Fund Management (UK) Ltd | 20,032 | $61,498 | 0.05% |
| Rock Springs Capital Management LP | 524,944 | $1,559,084 | 0.04% |
| Hunting Hill Global Capital, LLC | 10,000 | $29,700 | 0.02% |